seperator

Our SNIM® RNA platform

seperator

 

Transcript Therapies are exciting alternatives to gene therapies and protein-based drugs. Messenger RNA is a single-strand of nucleotides that transcribes genetic information found in DNA into a message that can be read by the machinery of a cell and translated into proteins that the body needs to function. Historically, mRNA has not been usable as a therapeutic agent because when delivered into the body it activates the immune system and is highly unstable. In addition, in order to be functional, mRNA must enter the target cells of interest by crossing the cell membrane, which requires a carrier system to transport it into the cells. Ethris has developed two technology platforms to enable the use of messenger RNA as a therapeutic agent: The Stabilized Non-Immunogenic mRNA (SNIM®RNA) for transcript therapy, as well as proprietary delivery technologies for SNIM® RNA delivery. Our SNIM® RNA Technology is a novel nucleic acid therapy platform based on stabilized non-immunogenic mRNA. SNIM® RNAs overcome the innate instability and immunity of mRNA. They evade the innate immune system due to chemical modifications in their building blocks. SNIM® RNAs can be administered repeatedly, leading to sustained production of therapeutically active proteins within the human body. This can be used in the therapy of hereditary diseases, as an alternative to protein therapy, and in regenerative medicine.

STABILIZED NON-IMMUNOGENIC MESSENGER RNA – SNIM® RNA

seperator

Therapeutic Focus

seperator

 

Our initial focus is to leverage our pioneering SNIM® RNA technology platform to develop therapies for severe pulmonary diseases, especially those with high unmet need such as Primary Ciliary Dyskinesia (PCD). Beyond this, the versatility of our first-in-class biopharmaceutical platform for replacing or augmenting missing or non-functional proteins will ultimately enable us to address an array of diverse and challenging disease indications.

Find out more about our approach to treating PCD here, and view our full therapeutic pipeline here. 

seperator

Scientific Publications

seperator

 

W. Zhang, R.E. De La Vega, M.J. Coenen, S.A. Muller, C.J. Peniche Silva, M.K. Aneja, C. Plank, M. van Griensven, C.H. Evans, E.R. Balmayor, An Improved, Chemically Modified RNA Encoding BMP-2 Enhances Osteogenesis In Vitro and In Vivo, Tissue Eng Part A, 25 (2019) 131-144. – Learn more.

Z. Trepotec, E. Lichtenegger, C. Plank, M.K. Aneja, C. Rudolph, Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases, Mol Ther, 27 (2019) 794-802. – Learn more.

Z. Trepotec, J. Geiger, C. Plank, M.K. Aneja, C. Rudolph, Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life, RNA, 25 (2019) 507-518. – Learn more.

Z. Trepotec, M.K. Aneja, J. Geiger, G. Hasenpusch, C. Plank, C. Rudolph, Maximizing the Translational Yield of mRNA Therapeutics by Minimizing 5′-UTRs, Tissue Eng Part A, 25 (2019) 69-79. – Learn more.

E. Herbst, F.B. Imhoff, P. Foehr, S. Milz, C. Plank, C. Rudolph, G. Hasenpusch, J.P. Geiger, M.K. Aneja, K. Groth, S. Vogt, A.B. Imhoff, A. Schmitt, Chemically Modified Messenger RNA: Modified RNA Application for Treatment of Achilles Tendon Defects, Tissue Eng Part A, 25 (2019) 113-120. – Learn more.

M. Holstein, C. Mesa-Nunez, C. Miskey, E. Almarza, V. Poletti, M. Schmeer, E. Grueso, J.C. Ordonez Flores, D. Kobelt, W. Walther, M.K. Aneja, J. Geiger, H.B. Bonig, Z. Izsvak, M. Schleef, C. Rudolph, F. Mavilio, J.A. Bueren, G. Guenechea, Z. Ivics, Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors, Mol Ther, 26 (2018) 1137-1153. – Learn more.

K. Hirschberger, A. Jarzebinska, E. Kessel, V. Kretzschmann, M.K. Aneja, C. Dohmen, A. Herrmann-Janson, E. Wagner, C. Plank, C. Rudolph, Exploring Cytotoxic mRNAs as a Novel Class of Anti-cancer Biotherapeutics, Mol Ther Methods Clin Dev, 8 (2018) 141-151. – Learn more.

B. Connor, E. Firmin, A. McCaughey-Chapman, R. Monk, K. Lee, S. Liot, J. Geiger, C. Rudolph, K. Jones, Conversion of adult human fibroblasts into neural precursor cells using chemically modified mRNA, Heliyon, 4 (2018) e00918. – Learn more.

M. Utzinger, A. Jarzebinska, N. Haag, M. Schweizer, G. Winter, C. Dohmen, C. Rudolph, C. Plank, cmRNA/lipoplex encapsulation in PLGA microspheres enables transfection via calcium phosphate cement (CPC)/PLGA composites, J Control Release, 249 (2017) 143-149. – Learn more.

E. Schrom, M. Huber, M. Aneja, C. Dohmen, D. Emrich, J. Geiger, G. Hasenpusch, A. Herrmann-Janson, V. Kretzschmann, O. Mykhailyk, T. Pasewald, P. Oak, A. Hilgendorff, D. Wohlleber, H.G. Hoymann, D. Schaudien, C. Plank, C. Rudolph, R. Kubisch-Dohmen, Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNA, Mol Ther Nucleic Acids, 7 (2017) 350-365. – Learn more.

K. Groth, T. Berezhanskyy, M.K. Aneja, J. Geiger, M. Schweizer, L. Maucksch, T. Pasewald, T. Brill, B. Tigani, E. Weber, C. Rudolph, G. Hasenpusch, Tendon healing induced by chemically modified mRNAs, Eur Cell Mater, 33 (2017) 294-307. – Learn more.

E.R. Balmayor, J.P. Geiger, C. Koch, M.K. Aneja, M. van Griensven, C. Rudolph, C. Plank, Modified mRNA for BMP-2 in Combination with Biomaterials Serves as a Transcript-Activated Matrix for Effectively Inducing Osteogenic Pathways in Stem Cells, Stem Cells Dev, 26 (2017) 25-34. – Learn more.

Z.S. Badieyan, T. Pasewald, O. Mykhaylyk, C. Rudolph, C. Plank, Efficient ex vivo delivery of chemically modified messenger RNA using lipofection and magnetofection, Biochem Biophys Res Commun, 482 (2017) 796-801. – Learn more.

A. Jarzebinska, T. Pasewald, J. Lambrecht, O. Mykhaylyk, L. Kummerling, P. Beck, G. Hasenpusch, C. Rudolph, C. Plank, C. Dohmen, A Single Methylene Group in Oligoalkylamine-Based Cationic Polymers and Lipids Promotes Enhanced mRNA Delivery, Angew Chem Int Ed Engl, 55 (2016) 9591-9595. – Learn more.

M. Ferizi, M.K. Aneja, E.R. Balmayor, Z.S. Badieyan, O. Mykhaylyk, C. Rudolph, C. Plank, Human cellular CYBA UTR sequences increase mRNA translation without affecting the half-life of recombinant RNA transcripts, Sci Rep, 6 (2016) 39149. – Learn more.

E.R. Balmayor, J.P. Geiger, M.K. Aneja, T. Berezhanskyy, M. Utzinger, O. Mykhaylyk, C. Rudolph, C. Plank, Chemically modified RNA induces osteogenesis of stem cells and human tissue explants as well as accelerates bone healing in rats, Biomaterials, 87 (2016) 131-146. – Learn more.

Z.S. Badieyan, T. Berezhanskyy, M. Utzinger, M.K. Aneja, D. Emrich, R. Erben, C. Schuler, P. Altpeter, M. Ferizi, G. Hasenpusch, C. Rudolph, C. Plank, Transcript-activated collagen matrix as sustained mRNA delivery system for bone regeneration, J Control Release, 239 (2016) 137-148. – Learn more.

M. Ferizi, C. Leonhardt, C. Meggle, M.K. Aneja, C. Rudolph, C. Plank, J.O. Radler, Stability analysis of chemically modified mRNA using micropattern-based single-cell arrays, Lab Chip, 15 (2015) 3561-3571. – Learn more.

  1. W. Zhang, R.E. De La Vega, M.J. Coenen, S.A. Muller, C.J. Peniche Silva, M.K. Aneja, C. Plank, M. van Griensven, C.H. Evans, E.R. Balmayor, An Improved, Chemically Modified RNA Encoding BMP-2 Enhances Osteogenesis In Vitro and In Vivo, Tissue Eng Part A, 25 (2019) 131-144. – Learn more.
  2. Z. Trepotec, E. Lichtenegger, C. Plank, M.K. Aneja, C. Rudolph, Delivery of mRNA Therapeutics for the Treatment of Hepatic Diseases, Mol Ther, 27 (2019) 794-802. – Learn more.
  3. Z. Trepotec, J. Geiger, C. Plank, M.K. Aneja, C. Rudolph, Segmented poly(A) tails significantly reduce recombination of plasmid DNA without affecting mRNA translation efficiency or half-life, RNA, 25 (2019) 507-518. – Learn more.
  4. Z. Trepotec, M.K. Aneja, J. Geiger, G. Hasenpusch, C. Plank, C. Rudolph, Maximizing the Translational Yield of mRNA Therapeutics by Minimizing 5′-UTRs, Tissue Eng Part A, 25 (2019) 69-79. – Learn more.
  5. E. Herbst, F.B. Imhoff, P. Foehr, S. Milz, C. Plank, C. Rudolph, G. Hasenpusch, J.P. Geiger, M.K. Aneja, K. Groth, S. Vogt, A.B. Imhoff, A. Schmitt, Chemically Modified Messenger RNA: Modified RNA Application for Treatment of Achilles Tendon Defects, Tissue Eng Part A, 25 (2019) 113-120. – Learn more.
  6. M. Holstein, C. Mesa-Nunez, C. Miskey, E. Almarza, V. Poletti, M. Schmeer, E. Grueso, J.C. Ordonez Flores, D. Kobelt, W. Walther, M.K. Aneja, J. Geiger, H.B. Bonig, Z. Izsvak, M. Schleef, C. Rudolph, F. Mavilio, J.A. Bueren, G. Guenechea, Z. Ivics, Efficient Non-viral Gene Delivery into Human Hematopoietic Stem Cells by Minicircle Sleeping Beauty Transposon Vectors, Mol Ther, 26 (2018) 1137-1153. – Learn more.
  7. K. Hirschberger, A. Jarzebinska, E. Kessel, V. Kretzschmann, M.K. Aneja, C. Dohmen, A. Herrmann-Janson, E. Wagner, C. Plank, C. Rudolph, Exploring Cytotoxic mRNAs as a Novel Class of Anti-cancer Biotherapeutics, Mol Ther Methods Clin Dev, 8 (2018) 141-151. – Learn more.
  8. B. Connor, E. Firmin, A. McCaughey-Chapman, R. Monk, K. Lee, S. Liot, J. Geiger, C. Rudolph, K. Jones, Conversion of adult human fibroblasts into neural precursor cells using chemically modified mRNA, Heliyon, 4 (2018) e00918. – Learn more.
  9. M. Utzinger, A. Jarzebinska, N. Haag, M. Schweizer, G. Winter, C. Dohmen, C. Rudolph, C. Plank, cmRNA/lipoplex encapsulation in PLGA microspheres enables transfection via calcium phosphate cement (CPC)/PLGA composites, J Control Release, 249 (2017) 143-149. – Learn more.
  10. E. Schrom, M. Huber, M. Aneja, C. Dohmen, D. Emrich, J. Geiger, G. Hasenpusch, A. Herrmann-Janson, V. Kretzschmann, O. Mykhailyk, T. Pasewald, P. Oak, A. Hilgendorff, D. Wohlleber, H.G. Hoymann, D. Schaudien, C. Plank, C. Rudolph, R. Kubisch-Dohmen, Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNA, Mol Ther Nucleic Acids, 7 (2017) 350-365. – Learn more.
  11. K. Groth, T. Berezhanskyy, M.K. Aneja, J. Geiger, M. Schweizer, L. Maucksch, T. Pasewald, T. Brill, B. Tigani, E. Weber, C. Rudolph, G. Hasenpusch, Tendon healing induced by chemically modified mRNAs, Eur Cell Mater, 33 (2017) 294-307. – Learn more.
  12. E.R. Balmayor, J.P. Geiger, C. Koch, M.K. Aneja, M. van Griensven, C. Rudolph, C. Plank, Modified mRNA for BMP-2 in Combination with Biomaterials Serves as a Transcript-Activated Matrix for Effectively Inducing Osteogenic Pathways in Stem Cells, Stem Cells Dev, 26 (2017) 25-34. – Learn more.
  13. Z.S. Badieyan, T. Pasewald, O. Mykhaylyk, C. Rudolph, C. Plank, Efficient ex vivo delivery of chemically modified messenger RNA using lipofection and magnetofection, Biochem Biophys Res Commun, 482 (2017) 796-801. – Learn more.
  14. A. Jarzebinska, T. Pasewald, J. Lambrecht, O. Mykhaylyk, L. Kummerling, P. Beck, G. Hasenpusch, C. Rudolph, C. Plank, C. Dohmen, A Single Methylene Group in Oligoalkylamine-Based Cationic Polymers and Lipids Promotes Enhanced mRNA Delivery, Angew Chem Int Ed Engl, 55 (2016) 9591-9595. – Learn more.
  15. M. Ferizi, M.K. Aneja, E.R. Balmayor, Z.S. Badieyan, O. Mykhaylyk, C. Rudolph, C. Plank, Human cellular CYBA UTR sequences increase mRNA translation without affecting the half-life of recombinant RNA transcripts, Sci Rep, 6 (2016) 39149. – Learn more.
  16. E.R. Balmayor, J.P. Geiger, M.K. Aneja, T. Berezhanskyy, M. Utzinger, O. Mykhaylyk, C. Rudolph, C. Plank, Chemically modified RNA induces osteogenesis of stem cells and human tissue explants as well as accelerates bone healing in rats, Biomaterials, 87 (2016) 131-146. – Learn more.
  17. Z.S. Badieyan, T. Berezhanskyy, M. Utzinger, M.K. Aneja, D. Emrich, R. Erben, C. Schuler, P. Altpeter, M. Ferizi, G. Hasenpusch, C. Rudolph, C. Plank, Transcript-activated collagen matrix as sustained mRNA delivery system for bone regeneration, J Control Release, 239 (2016) 137-148. – Learn more.
  18. M. Ferizi, C. Leonhardt, C. Meggle, M.K. Aneja, C. Rudolph, C. Plank, J.O. Radler, Stability analysis of chemically modified mRNA using micropattern-based single-cell arrays, Lab Chip, 15 (2015) 3561-3571. – Learn more.

Learn more about our pipeline.

GO TO PIPELINE